AR076083A1 - Anticuerpo monoclonal anti-rhesus d - Google Patents

Anticuerpo monoclonal anti-rhesus d

Info

Publication number
AR076083A1
AR076083A1 ARP100100663A ARP100100663A AR076083A1 AR 076083 A1 AR076083 A1 AR 076083A1 AR P100100663 A ARP100100663 A AR P100100663A AR P100100663 A ARP100100663 A AR P100100663A AR 076083 A1 AR076083 A1 AR 076083A1
Authority
AR
Argentina
Prior art keywords
monoclonal antibody
antibody
rhesus
amino acid
acid sequence
Prior art date
Application number
ARP100100663A
Other languages
English (en)
Inventor
Romeuf Christophe De
Sylvie Jorieux
Christine Gaucher
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of AR076083A1 publication Critical patent/AR076083A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Abstract

Se posee un ácido nucleico que codifica la cadena pesada de un anticuerpo, un vector de expresion que lo comprende, una célula huésped, un método para producir el anticuerpo y una composicion farmacéutica. Reivindicacion 1: Un anticuerpo monoclonal anti-RhD, que es una inmunoglobulina IgG1 tetramérica compuesta de dos cadenas pesadas y dos cadenas livianas, la cadena pesada comprende la secuencia de aminoácido SEQ ID NO 2 y la cadena liviana comprende la secuencia de aminoácido SEQ ID NO 4.
ARP100100663A 2009-03-06 2010-03-05 Anticuerpo monoclonal anti-rhesus d AR076083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0951412A FR2942799B1 (fr) 2009-03-06 2009-03-06 Anticorps monoclonal anti-rhesus d

Publications (1)

Publication Number Publication Date
AR076083A1 true AR076083A1 (es) 2011-05-18

Family

ID=40902101

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100663A AR076083A1 (es) 2009-03-06 2010-03-05 Anticuerpo monoclonal anti-rhesus d

Country Status (16)

Country Link
US (1) US8404241B2 (es)
EP (1) EP2403529B1 (es)
JP (1) JP5474100B2 (es)
KR (1) KR101297343B1 (es)
CN (1) CN102341121B (es)
AR (1) AR076083A1 (es)
AU (1) AU2010219518B2 (es)
BR (1) BRPI1009241B1 (es)
CA (1) CA2753700C (es)
DK (1) DK2403529T3 (es)
ES (1) ES2533528T3 (es)
FR (1) FR2942799B1 (es)
IL (1) IL214755A (es)
PL (1) PL2403529T3 (es)
TW (1) TWI441921B (es)
WO (1) WO2010100383A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
PT2830658T (pt) * 2012-03-26 2018-12-28 Sanofi Sa Formulações de agente de ligação igg4 estável
MY173295A (en) * 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
CN114409791B (zh) * 2022-01-26 2023-01-24 南京医科大学 一种全人源抗人红细胞RhD全分子IgG及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2861079B1 (fr) * 2003-10-20 2007-09-28 Lab Francais Du Fractionnement Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
MX2007000644A (es) * 2004-07-20 2007-03-28 Symphogen As Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
BRPI0613259A2 (pt) * 2005-05-20 2010-12-28 Genentech Inc método de tratamento de amostra biológica e kit de diagnóstico
KR100991010B1 (ko) * 2005-05-26 2010-10-29 제넨테크, 인크. 인간화 항-ｃｄ４０ 항체 및 그의 사용 방법
WO2008121615A2 (en) * 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation

Also Published As

Publication number Publication date
EP2403529A1 (fr) 2012-01-11
FR2942799B1 (fr) 2011-02-25
US20110311556A1 (en) 2011-12-22
DK2403529T3 (en) 2015-04-13
KR101297343B1 (ko) 2013-08-20
BRPI1009241A2 (pt) 2016-10-11
AU2010219518B2 (en) 2012-09-20
IL214755A0 (en) 2011-11-30
IL214755A (en) 2017-03-30
WO2010100383A1 (fr) 2010-09-10
CA2753700C (fr) 2014-04-22
JP2012519478A (ja) 2012-08-30
CN102341121A (zh) 2012-02-01
US8404241B2 (en) 2013-03-26
KR20110140125A (ko) 2011-12-30
AU2010219518A1 (en) 2011-10-20
JP5474100B2 (ja) 2014-04-16
ES2533528T3 (es) 2015-04-10
PL2403529T3 (pl) 2015-07-31
CN102341121B (zh) 2015-07-08
CA2753700A1 (fr) 2010-09-10
BRPI1009241B1 (pt) 2019-11-05
FR2942799A1 (fr) 2010-09-10
EP2403529B1 (fr) 2014-12-31
TW201043693A (en) 2010-12-16
TWI441921B (zh) 2014-06-21

Similar Documents

Publication Publication Date Title
PE20140979A1 (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
CL2008002349A1 (es) Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células.
PE20141162A1 (es) Anticuerpos anti-il-23
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20171103A1 (es) Anticuerpos heterodimericos que se unen a cd3 y cd38
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
CU20190087A7 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
MX2014005108A (es) Constructos de polipeptidos y sus usos.
SG10201807877TA (en) Hybrid immunoglobulin containing non-peptidyl linkage
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20131209A1 (es) Anticuerpos anti-fap
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure